The findings of Xiao et al. suggest that the activity of LEP and PTTG1 could potentially be used as a molecular marker for identifying RPLS patients that might benefit from more intensive treatments. Here, PTTG1 is linked to Posterior Leukoencephalopathy Syndrome.